Drug intelligence / Profile preview

br3006-3

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR3006-3 is a component of the investigational drug series developed by Boryung Pharmaceutical for the treatment of diabetes mellitus. It is part of a set of related compounds (BR3006, BR3006-1, BR3006-2, and BR3006-3) being evaluated in clinical trials for their pharmacokinetics, safety profiles, and potential drug-drug interactions. The mechanism of action is currently undefined or not publicly disclosed[2][9]. The primary indication under investigation is type 2 diabetes mellitus[2][9].

Beyond the preview

Go deeper on br3006-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on br3006-3.

Explore the full profile